TOBRAMYCIN

Tobramycin Adverse Events Reported to the FDA Over Time

How are Tobramycin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Tobramycin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Tobramycin is flagged as the suspect drug causing the adverse event.

Most Common Tobramycin Adverse Events Reported to the FDA

What are the most common Tobramycin adverse events reported to the FDA?

Renal Failure Acute	78 (3.2%)
Pyrexia	61 (2.5%)
Drug Ineffective	34 (1.4%)
Blood Creatinine Increased	32 (1.31%)
Nausea	30 (1.23%)
Pneumonia	29 (1.19%)
Dehydration	28 (1.15%)
Tachycardia	28 (1.15%)
Hypotension	27 (1.11%)
Diarrhoea	25 (1.03%)
Haemodialysis	25 (1.03%)
	Show More
Vomiting	24 (.98%)
Drug Hypersensitivity	23 (.94%)
Pseudomembranous Colitis	22 (.9%)
Eye Irritation	21 (.86%)
Tinnitus	21 (.86%)
Condition Aggravated	20 (.82%)
Renal Impairment	20 (.82%)
Abdominal Pain	19 (.78%)
Clostridium Difficile Colitis	19 (.78%)
Vision Blurred	19 (.78%)
Visual Acuity Reduced	19 (.78%)
Dizziness	18 (.74%)
Dyspnoea	18 (.74%)
Ocular Hyperaemia	18 (.74%)
Pseudomonas Infection	18 (.74%)
Cough	17 (.7%)
Intraocular Pressure Increased	17 (.7%)
Staphylococcal Infection	17 (.7%)
Acute Generalised Exanthematous Pus...	16 (.66%)
Eye Pain	16 (.66%)
Drug Level Increased	15 (.62%)
Hypersensitivity	15 (.62%)
Neuralgic Amyotrophy	15 (.62%)
Septic Shock	15 (.62%)
Rash	14 (.57%)
Thrombocytopenia	14 (.57%)
Headache	13 (.53%)
Pruritus	13 (.53%)
Weight Decreased	13 (.53%)
Deafness Neurosensory	12 (.49%)
Disease Progression	12 (.49%)
Arthralgia	11 (.45%)
Balance Disorder	11 (.45%)
Eosinophilia	11 (.45%)
Eye Swelling	11 (.45%)
Eyelid Oedema	11 (.45%)
Febrile Neutropenia	11 (.45%)
Malaise	11 (.45%)
Multi-organ Failure	11 (.45%)
Renal Failure	11 (.45%)
Renal Tubular Necrosis	11 (.45%)
Angle Closure Glaucoma	10 (.41%)
C-reactive Protein Increased	10 (.41%)
Colitis	10 (.41%)
Hypoacusis	10 (.41%)
Hypoxia	10 (.41%)
Post Procedural Complication	10 (.41%)
Rash Maculo-papular	10 (.41%)
Sepsis	10 (.41%)
Bronchospasm	9 (.37%)
Cystic Fibrosis Lung	9 (.37%)
Erythema Of Eyelid	9 (.37%)
General Physical Condition Abnormal	9 (.37%)
Hepatitis Toxic	9 (.37%)
Liver Injury	9 (.37%)
Lung Disorder	9 (.37%)
Rash Erythematous	9 (.37%)
Atrial Fibrillation	8 (.33%)
Blood Urea Increased	8 (.33%)
Deafness	8 (.33%)
Decreased Appetite	8 (.33%)
Drug Interaction	8 (.33%)
Erythema	8 (.33%)
Infection	8 (.33%)
Inflammation	8 (.33%)
Lacrimation Increased	8 (.33%)
Overdose	8 (.33%)
Pain	8 (.33%)
Pancytopenia	8 (.33%)
Photophobia	8 (.33%)
Respiratory Failure	8 (.33%)
Abdominal Distension	7 (.29%)
Asthenia	7 (.29%)
Dialysis	7 (.29%)
Drug Toxicity	7 (.29%)
Dysgeusia	7 (.29%)
Dyspepsia	7 (.29%)
Eye Oedema	7 (.29%)
Eye Pruritus	7 (.29%)
Haemoptysis	7 (.29%)
Increased Upper Airway Secretion	7 (.29%)
Influenza Like Illness	7 (.29%)
Ocular Hypertension	7 (.29%)
Anaemia	6 (.25%)
Anuria	6 (.25%)
Chills	6 (.25%)
Conjunctivitis	6 (.25%)
Convulsion	6 (.25%)
Disease Recurrence	6 (.25%)
Face Oedema	6 (.25%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Tobramycin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Tobramycin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Tobramycin

What are the most common Tobramycin adverse events reported to the FDA?

Renal Disorders	135 (5.54%)
Epidermal And Dermal Conditions	132 (5.42%)
Respiratory	122 (5.01%)
Bacterial Infectious	105 (4.31%)
Infections - Pathogen Unspecified	103 (4.23%)
Gastrointestinal Signs	96 (3.94%)
Ocular Infections, Irritations And ...	93 (3.82%)
Neurological	80 (3.28%)
Body Temperature Conditions	62 (2.54%)
Eye	58 (2.38%)
Therapeutic And Nontherapeutic Effe...	55 (2.26%)
	Show More
Renal And Urinary Tract Investigati...	54 (2.22%)
Cardiac Arrhythmias	48 (1.97%)
Hepatic And Hepatobiliary	47 (1.93%)
Vision	46 (1.89%)
Allergic Conditions	44 (1.81%)
Electrolyte And Fluid Balance Condi...	43 (1.76%)
White Blood Cell	38 (1.56%)
Hearing	36 (1.48%)
Hematological And Lymphoid Tissue T...	34 (1.4%)
Hematology Investigations	33 (1.35%)
Gastrointestinal Motility And Defec...	31 (1.27%)
Decreased And Nonspecific Blood Pre...	28 (1.15%)
Physical Examination Topics	28 (1.15%)
Inner Ear And Viiith Cranial Nerve	26 (1.07%)
Peripheral Neuropathies	26 (1.07%)
Procedural And Device Related Injur...	25 (1.03%)
Joint	24 (.98%)
Medication Errors	24 (.98%)
Bronchial Disorders	23 (.94%)
Toxicology And Therapeutic Drug Mon...	21 (.86%)
Injuries	20 (.82%)
Neurological, Special Senses And Ps...	20 (.82%)
Anterior Eye Structural Change, Dep...	18 (.74%)
Cardiac And Vascular Investigations	18 (.74%)
Glaucoma And Ocular Hypertension	18 (.74%)
Muscle	18 (.74%)
Musculoskeletal And Connective Tiss...	17 (.7%)
Fungal Infectious	15 (.62%)
Anemias Nonhemolytic And Marrow Dep...	14 (.57%)
Gastrointestinal Inflammatory Condi...	14 (.57%)
Headaches	14 (.57%)
Platelet	14 (.57%)
Respiratory Disorders Congenital	14 (.57%)
Chemical Injury And Poisoning	13 (.53%)
Appetite And General Nutritional	12 (.49%)
Nephropathies	12 (.49%)
Respiratory And Pulmonary Investiga...	12 (.49%)
Angiedema And Urticaria	11 (.45%)
Lower Respiratory Tract Disorders	11 (.45%)
Ocular Sensory Symptoms	11 (.45%)
Protein And Chemistry Analyses	11 (.45%)
Gastrointestinal Ulceration And Per...	10 (.41%)
Hepatobiliary	9 (.37%)
Seizures	9 (.37%)
Microbiology And Serology	8 (.33%)
Water, Electrolyte And Mineral	8 (.33%)
Administration Site Reactions	7 (.29%)
Anxiety Disorders	7 (.29%)
Arteriosclerosis, Stenosis, Vascula...	7 (.29%)
Skin Vascular Abnormalities	7 (.29%)
Urinary Tract Signs	7 (.29%)
Coagulopathies And Bleeding Diathes...	6 (.25%)
Hemolyses And Related Conditions	6 (.25%)
Lifestyle Issues	6 (.25%)
Metabolic, Nutritional And Blood Ga...	6 (.25%)
Product Quality Issues	6 (.25%)
Enzyme	5 (.21%)
Therapeutic Procedures And Supporti...	5 (.21%)
Viral Infectious	5 (.21%)
Bone And Joint Injuries	4 (.16%)
Exocrine Pancreas Conditions	4 (.16%)
Fatal Outcomes	4 (.16%)
Immunology And Allergy	4 (.16%)
Investigations, Imaging And Histopa...	4 (.16%)
Neonatal And Perinatal Conditions	4 (.16%)
Ocular Neuromuscular	4 (.16%)
Oral Soft Tissue Conditions	4 (.16%)
Skin And Subcutaneous Tissue	4 (.16%)
Vascular Hypertensive	4 (.16%)
Aural	3 (.12%)
Cardiac Disorder Signs	3 (.12%)
Central Nervous System Vascular	3 (.12%)
Eye Therapeutic Procedures	3 (.12%)
Gastrointestinal Stenosis And Obstr...	3 (.12%)
Gastrointestinal Therapeutic Proced...	3 (.12%)
Glucose Metabolism Disorders	3 (.12%)
Immune	3 (.12%)
Movement Disorders	3 (.12%)
Neuromuscular	3 (.12%)
Vascular	3 (.12%)
Vascular Hemorrhagic	3 (.12%)
Acid-base	2 (.08%)
Ancillary Infectious Topics	2 (.08%)
Bone Disorders	2 (.08%)
Bone, Calcium, Magnesium And Phosph...	2 (.08%)
Deliria	2 (.08%)
Dental And Gingival Conditions	2 (.08%)
Depressed Mood Disorders	2 (.08%)
Disturbances In Thinking	2 (.08%)
Encephalopathies	2 (.08%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Tobramycin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Tobramycin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.